Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1306    

    Article Cited by others

EDITORIAL

What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?

Sharma Surendra K, Dheda Keertan

Year : 2019| Volume: 149| Issue : 3 | Page no: 309-312

   This article has been cited by
 
1 Comparing the impact of genotypic based diagnostic algorithm on time to treatment initiation and treatment outcomes among drug-resistant tuberculosis patients in Amhara region, Ethiopia
Getahun Molla Kassa,Mehari Woldemariam Merid,Atalay Goshu Muluneh,Haileab Fekadu Wolde,Frederick Quinn
PLOS ONE. 2021; 16(2): e0246938
[Pubmed]  [Google Scholar] [DOI]
2 Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India
Shubhangi Dhakulkar,Mrinalini Das,Narendra Sutar,Vikas Oswal,Daksha Shah,Shilpa Ravi,Dipa Vengurlekar,Vijay Chavan,Lorraine Rebello,Augusto C. Meneguim,Aparna Iyer,Homa Mansoor,Stobdan Kalon,Shrikala Acharya,Gabriella Ferlazzo,Petros Isaakidis,Harshad P. Thakur,Yatin N. Dholakia
PLOS ONE. 2021; 16(2): e0246639
[Pubmed]  [Google Scholar] [DOI]
3 A Rare Case of Tuberculosis Cutis Colliquative
Shravya Rimmalapudi,Amruta D. Morey,Bhushan Madke,Adarsh Lata Singh,Sugat Jawade
Journal of Evolution of Medical and Dental Sciences. 2021; 10(5): 305
[Pubmed]  [Google Scholar] [DOI]
4 Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
Hamzah Z. Farooq,Daniela M. Cirillo,Doris Hillemann,David Wyllie,Marieke J. van der Werf,Csaba Ködmön,Vlad Nikolayevskyy
Emerging Infectious Diseases. 2021; 27(3): 985
[Pubmed]  [Google Scholar] [DOI]
5 Performance of the GenoType MTBDRsl V 2.0 for detecting second-line drugs resistance of Mycobacterium tuberculosis isolates in Tunisia
Imen Bouzouita,Henda Draoui,Andrea Maurizio Cabibbe,Leila Essalah,Sana Bejaoui,Alberto Trovato,Féričle Messadi,Daniela Maria Cirillo,Leila Slim-Saidi
Research in Microbiology. 2021; : 103816
[Pubmed]  [Google Scholar] [DOI]
6 Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update
Sambuddha Ghosh,Lusine Breitscheidel,Natasa Lazarevic,Alexandra Martin,Jeffrey Hafkin,Norbert Hittel
European Respiratory Journal. 2021; 57(5): 2002483
[Pubmed]  [Google Scholar] [DOI]
7 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
Dumitru Chesov,Jan Heyckendorf,Sofia Alexandru,Ana Donica,Elena Chesov,Maja Reimann,Valeriu Crudu,Victor Botnaru,Christoph Lange
European Respiratory Journal. 2021; 57(6): 2002544
[Pubmed]  [Google Scholar] [DOI]
8 Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: A qualitative study
Mrinalini Das,Taanya Mathur,Shilpa Ravi,Augusto C. Meneguim,Aparna Iyer,Homa Mansoor,Stobdan Kalon,Farah Naz Hossain,Shrikala Acharya,Gabriella Ferlazzo,Petros Isaakidis,Harshad P. Thakur,Nora Engel
PLOS ONE. 2021; 16(3): e0248408
[Pubmed]  [Google Scholar] [DOI]
9 National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study
Habteyes Tola,K Holakouie-Naieni,Mohammad Ali Mansournia,Mehdi Yaseri,Dinka Fikadu Gamtesa,Ephrem Tesfaye,Zemedu Mahamed,Million Molla Sisay
BMJ Open. 2021; 11(8): e040862
[Pubmed]  [Google Scholar] [DOI]
10 Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review
Klaudia T. Angula,Lesetja J. Legoabe,Richard M. Beteck
Pharmaceuticals. 2021; 14(5): 461
[Pubmed]  [Google Scholar] [DOI]
11 Potential value of urine lateral-flow lipoarabinomannan (LAM) test for diagnosing tuberculosis among severely acute malnourished children
Birgit Schramm,Rodrigue C. Nganaboy,Piex Uwiragiye,Didier Mukeba,Aboubacar Abdoubara,Illa Abdou,Jean-Claude Nshimiymana,Seyni Sounna,Laurent Hiffler,Laurence Flevaud,Helena Huerga,Frederick Quinn
PLOS ONE. 2021; 16(5): e0250933
[Pubmed]  [Google Scholar] [DOI]
12 Clofazimine functionalized polymeric nanoparticles for brain delivery in the tuberculosis treatment
Renata Ribeiro de Castro,Flavia Almada do Carmo,Cláudia Martins,Alice Simon,Valeria Pereira de Sousa,Carlos Rangel Rodrigues,Lucio Mendes Cabral,Bruno Sarmento
International Journal of Pharmaceutics. 2021; 602: 120655
[Pubmed]  [Google Scholar] [DOI]
13 New Developments and Insights in the Improvement of Mycobacterium tuberculosis Vaccines and Diagnostics Within the End TB Strategy
Juan Ignacio García,Anna Allué-Guardia,Radhika P. Tampi,Blanca I. Restrepo,Jordi B. Torrelles
Current Epidemiology Reports. 2021;
[Pubmed]  [Google Scholar] [DOI]
14 Collaborative tuberculosis/HIV activities in the European Region
Gerard de Vries,Sarah van de Berg,Anke van Dam,Sayohat Hasanova,Manish Pareek,Marieke J. van der Werf,Daria N. Podlekareva
ERJ Open Research. 2021; 7(1): 00721-2020
[Pubmed]  [Google Scholar] [DOI]
15 Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia
Rika Yuliwulandari,Kinasih Prayuni,Intan Razari,Retno W Susilowati,Yenni Zulhamidah,Soedarsono Soedarsono,Abdul Salam M Sofro,Katsushi Tokunaga
Pharmacogenomics. 2021; 22(3): 157
[Pubmed]  [Google Scholar] [DOI]
16 Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications
Aliabbas A. Husain,Andreas Kupz,Rajpal S. Kashyap
Epidemiology and Health. 2021; 43: e2021022
[Pubmed]  [Google Scholar] [DOI]
17 Determination of isoniazid and pyridoxine in plasma sample of tuberculosis patients by micellar liquid chromatography
María Ángeles Goberna-Bravo,Jaume Albiol-Chiva,Juan Peris-Vicente,Samuel Carda-Broch,Josep Esteve-Romero
Microchemical Journal. 2021; 167: 106317
[Pubmed]  [Google Scholar] [DOI]
18 Immunotherapeutic effect of adenovirus encoding antimicrobial peptides in experimental pulmonary tuberculosis
Octavio Ramos-Espinosa,Dulce Mata-Espinosa,Alejandro Francisco-Cruz,Manuel Othoniel López-Torres,Sujhey Hernández-Bazán,Jorge Barrios-Payán,Brenda Marquina-Castillo,Marta Carretero,Marcela del Río,Rogelio Hernández-Pando
Journal of Leukocyte Biology. 2021;
[Pubmed]  [Google Scholar] [DOI]
19 Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults
Lauren S. Peetluk,Felipe M. Ridolfi,Peter F. Rebeiro,Dandan Liu,Valeria C Rolla,Timothy R. Sterling
BMJ Open. 2021; 11(3): e044687
[Pubmed]  [Google Scholar] [DOI]
20 Validation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients
NS Gomathi,Manjula Singh,VP Myneedu,DS Chauhan,Srikanth Tripathy,Rohit Sarin,Anant Mohan,Anuj Bhatnagar,JitenSingh Khangembam,T Kannan,MV V. Rao,Jyoti Logani,Bindu Dey,RR Gangakhedkar,Soumya Swaminathan,UrvashiB Singh
Indian Journal of Medical Research. 2020; 152(5): 482
[Pubmed]  [Google Scholar] [DOI]
21 Changes in treatment for multidrug-resistant tuberculosis according to national income
Nakwon Kwak,Nicholas Winters,Jonathon R. Campbell,Edward D. Chan,Medea Gegia,Christoph Lange,Myungsun Lee,Vladimir Milanov,Dick Menzies,Jae-Joon Yim
European Respiratory Journal. 2020; 56(5): 2001394
[Pubmed]  [Google Scholar] [DOI]
22 Transient Bartter-like syndrome in a child with extensively drug-resistant tuberculosis: Answers
Vishrutha Sujith Poojari,Ira Shah,Naman S. Shetty,Akanksha Jaiswal
Pediatric Nephrology. 2020;
[Pubmed]  [Google Scholar] [DOI]
23 Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
Jonathon R. Campbell,Dennis Falzon,Fuad Mirzayev,Ernesto Jaramillo,Giovanni Battista Migliori,Carole D. Mitnick,Norbert Ndjeka,Dick Menzies
Emerging Infectious Diseases. 2020; 26(3)
[Pubmed]  [Google Scholar] [DOI]
24 Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa
Martha L. van der Walt,Karen Shean,Piet Becker,Karen H. Keddy,Joey Lancaster
Antimicrobial Agents and Chemotherapy. 2020; 65(1): e00744-20
[Pubmed]  [Google Scholar] [DOI]
25 Correspondence regarding “Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa”
Erika Mohr-Holland,Anja Reuter,Jennifer Hughes,Johnny Daniels,Busisiwe Beko,Goodman Makhanda,Virginia De Avezedo,Yulene Kock,Helen Cox,Jennifer Furin,Laura Trivino Duran,Petros Isaakidis,Gabriella Ferlazzo
European Respiratory Journal. 2020; 56(1): 2000837
[Pubmed]  [Google Scholar] [DOI]
26 Retrospective analysis of multidrug-resistant tuberculosis case notifications in Australia (1999–2018)
Hendrik S Camphor,Kerri Viney,Ben Polkinghorne,Kate Pennington
Communicable Diseases Intelligence. 2020; 44
[Pubmed]  [Google Scholar] [DOI]
27 Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study
Samiksha Ghimire,Samriddhi Karki,Bhagwan Maharjan,Jos G W Kosterink,Daan J Touw,Tjip S van der Werf,Bhabana Shrestha,Jan-Willem Alffenaar
BMJ Open Respiratory Research. 2020; 7(1): e000606
[Pubmed]  [Google Scholar] [DOI]
28 Unfavorable outcomes to second-line tuberculosis therapy among HIV-infected versus HIV-uninfected patients in sub-Saharan Africa: A systematic review and meta-analysis
Dumessa Edessa,Mekonnen Sisay,Yadeta Dessie,Qigui Yu
PLOS ONE. 2020; 15(8): e0237534
[Pubmed]  [Google Scholar] [DOI]
29 Targeted next-generation sequencing of sputum for diagnosis of drug-resistant TB: results of a national survey in Democratic Republic of the Congo
Michel Kaswa Kayomo,Vital Nkake Mbula,Muriel Aloni,Emmanuel André,Leen Rigouts,Fairouz Boutachkourt,Bouke C. de Jong,Nicolas M. Nkiere,Anna S. Dean
Scientific Reports. 2020; 10(1)
[Pubmed]  [Google Scholar] [DOI]
30 Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data
Anna S. Dean,Matteo Zignol,Andrea Maurizio Cabibbe,Dennis Falzon,Philippe Glaziou,Daniela Maria Cirillo,Claudio U. Köser,Lice Y. Gonzalez-Angulo,Olga Tosas-Auget,Nazir Ismail,Sabira Tahseen,Maria Cecilia G. Ama,Alena Skrahina,Natavan Alikhanova,S. M. Mostofa Kamal,Katherine Floyd,Madhukar Pai
PLOS Medicine. 2020; 17(1): e1003008
[Pubmed]  [Google Scholar] [DOI]
31 Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens: a systematic review
Emmanuel Rivičre,Michael G. Whitfield,Jochem Nelen,Tim H. Heupink,Annelies Van Rie
Clinical Microbiology and Infection. 2020;
[Pubmed]  [Google Scholar] [DOI]
32 Translating scientific discoveries during pandemics: ensuring equity for people affected by COVID-19 and tuberculosis
Jessica Carter,Jon S. Friedland,Daniela E. Kirwan,Ruvandhi R. Nathavitharana
ERJ Open Research. 2020; 6(4): 00562-2020
[Pubmed]  [Google Scholar] [DOI]
33 PE_PGRS proteins of Mycobacterium tuberculosis: A specialized molecular task force at the forefront of host–pathogen interaction
Flavio De Maio,Rita Berisio,Riccardo Manganelli,Giovanni Delogu
Virulence. 2020; 11(1): 898
[Pubmed]  [Google Scholar] [DOI]
34 Tuberculosis treatment in children: the changing landscape
Julie Huynh,Guy Thwaites,Ben J Marais,H Simon Schaaf
Paediatric Respiratory Reviews. 2020;
[Pubmed]  [Google Scholar] [DOI]
35 Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved In Vitro Th1-Type Cytokine Recall Responses in Human Whole Blood
Babatunde Ayodeji Adeagbo,Akintunde Oluseto Akinlalu,Tony Phan,Jeff Guderian,Gerhardt Boukes,Elize Willenburg,Caryn Fenner,Oluseye Oladotun Bolaji,Christopher B. Fox
ACS Omega. 2020;
[Pubmed]  [Google Scholar] [DOI]
36 Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study
Simone HJ van den Elsen,Marieke GG Sturkenboom,Onno Akkerman,Linda Barkane,Judith Bruchfeld,Geoffrey Eather,Scott K Heysell,Henadz Hurevich,Liga Kuksa,Heinke Kunst,Johanna Kuhlin,Katerina Manika,Charalampos Moschos,Stellah G Mpagama,Marcela Muńoz Torrico,Alena Skrahina,Giovanni Sotgiu,Marina Tadolini,Simon Tiberi,Francesca Volpato,Tjip S van der Werf,Malcolm R Wilson,Joaquin Zúńiga,Daan J Touw,Giovanni B Migliori,Jan-Willem Alffenaar
BMJ Open. 2020; 10(6): e035350
[Pubmed]  [Google Scholar] [DOI]
37 Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study
Mengqiu Gao,Jingtao Gao,Li Xie,Guihui Wu,Wei Chen,Yu Chen,Yi Pei,Guobao Li,Yuhong Liu,Wei Shu,Lin Fan,Qianhong Wu,Juan Du,Xiaohong Chen,Peijun Tang,Yu Xiong,Mingwu Li,Qingshan Cai,Long Jin,Zaoxian Mei,Yu Pang,Liang Li
Clinical Microbiology and Infection. 2020;
[Pubmed]  [Google Scholar] [DOI]
38 Evolution of newer regimens in TB from RNTCP to NTEP
Aditi Gupta,Vishal Chopra
Indian Journal of Tuberculosis. 2020;
[Pubmed]  [Google Scholar] [DOI]
39 Total Synthesis and Antimycobacterial Activity of Ohmyungsamycin A, Deoxyecumicin, and Ecumicin
Paige M. E. Hawkins,Wendy Tran,Gayathri Nagalingam,Chen-Yi Cheung,Andrew M. Giltrap,Gregory M. Cook,Warwick J. Britton,Richard J. Payne
Chemistry – A European Journal. 2020;
[Pubmed]  [Google Scholar] [DOI]
40 First case report in Latin America: Oral treatment of multidrug-resistant tuberculosis with delamanid and bedaquiline in combination with linezolid, moxifloxacin and clofazimine following a DRESS syndrome in a peruvian patient
S. Pecho-Silva,A.C. Navarro-Solsol
Pulmonology. 2020;
[Pubmed]  [Google Scholar] [DOI]
41 Tuberculosis in childhood and adolescence: a view from different perspectives
Tony T. Tahan,Betina M.A. Gabardo,Andrea M.O. Rossoni
Jornal de Pediatria (Versăo em Portuguęs). 2020; 96: 99
[Pubmed]  [Google Scholar] [DOI]
42 A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis
Karen Cohen,Gary Maartens
Expert Opinion on Drug Safety. 2019;
[Pubmed]  [Google Scholar] [DOI]
43 Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB
Kaksha Sankhe,Tabassum Khan,Chintan Bhavsar,Munira Momin,Abdelwahab Omri
Expert Opinion on Drug Delivery. 2019; 16(5): 525
[Pubmed]  [Google Scholar] [DOI]
44 Drug-resistant tuberculosis: Progress towards shorter and safer regimens
Kavitha Saravu,Madhukar Pai
Lung India. 2019; 36(5): 373
[Pubmed]  [Google Scholar] [DOI]
45 What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
SurendraK Sharma,Keertan Dheda
Indian Journal of Medical Research. 2019; 149(3): 309
[Pubmed]  [Google Scholar] [DOI]

 

Read this article